Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | RAB9A | P51151 | 10/20 | 0.39 |
| ▸ | NPC1 | O15118 | 8/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120992 | 0.86 | S1PR1 (0.45) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL3350172 | 0.85 | MAPK1 (0.41) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL10154815 | 0.82 | RAB9A (0.46) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL19364783 | 0.79 | RAB9A (0.42) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL21350422 | 0.78 | S1PR1 (0.40) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL2791170 | 0.76 | ALDH1A1 (0.43) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL456435 | 0.74 | PPARA (0.43) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL11928813 | 0.74 | RAB9A (0.39) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL440363 | 0.74 | SMN1; SMN2 (0.42) | S1PR1S1PR3ALDH1A1RAB9ANPC1 | |
| SCHEMBL1162479 | 0.74 | VHL (0.50) | S1PR1S1PR3ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210969-B1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO (JP) | 2021-04-28 | — | — | EP | disclosed |
| US-10676438-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10570093-B2 | — | — | 2020-02-25 | — | — | US | disclosed |
| US-10196358-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-05 | — | — | US | disclosed |
| US-20180346422-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-06 | — | — | US | disclosed |
| US-20170334855-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-23 | — | — | US | disclosed |
| US-9809544-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-11-07 | — | — | US | disclosed |
| EP-3210969-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO Pharmaceutical Co., Ltd. (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-20170217888-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD (JP) | 2017-08-03 | — | — | US | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | S1PR1 123/4885S1PR3 158/4885ALDH1A1 1293/4885 |
| US-10570093-B2 | — | KCNQ5, KCNQ2, KCNQ1 | S1PR1 2554/4885S1PR3 2846/4885ALDH1A1 818/4885 |
| US-20170334855-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | S1PR1 2746/4885S1PR3 3039/4885ALDH1A1 2411/4885 |
| US-20170217888-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | S1PR1 2746/4885S1PR3 3039/4885ALDH1A1 2411/4885 |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | S1PR1 2746/4885S1PR3 3039/4885ALDH1A1 2411/4885 |
| US-20180346422-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | S1PR1 2746/4885S1PR3 3039/4885ALDH1A1 2411/4885 |
| US-10676438-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | S1PR1 2746/4885S1PR3 3039/4885ALDH1A1 2411/4885 |
| US-10196358-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | S1PR1 2746/4885S1PR3 3039/4885ALDH1A1 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.